[
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The effect of alirocumab treatment on glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) was also evaluated according to DM status throughout the studies using descriptive statistics conducted on the safety population.Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Results\nStudy Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).Safety Analysis\nOverall, the incidence of TEAEs was similar between groups, occurring in 79.9% with DM and 79.8% without DM in alirocumab-treated individuals versus 82.0% and 81.0% in the placebo groups, respectively (Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Study Participants\nIn total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In total, 30.1% of alirocumab-treated individuals (n = 699) and 30.2% of those receiving placebo (n = 355) were classified as having DM at baseline (n = 1625 and n = 820, respectively, were classified as not having diabetes) (Table 1; Supplementary Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Change from baseline of lipids and achievement of LDL-C < 70 mg/dL at week 24 (intention-to-treat population)\n\n\n\n\nAlirocumab 150 mg Q2W pool (n = 2416)\nAlirocumab 75/150 mg Q2W pool (n = 1043)\n\n\nIndividuals with DM (n = 836)\nIndividuals without DM (n = 1580)\nIndividuals with DM (n = 202)\nIndividuals without DM (n = 841)\n\n\nAlirocumab (n = 556)\nPlacebo (n = 280)\nAlirocumab (n = 1045)\nPlacebo (n = 535)\nAlirocumab (n = 132)\nPlacebo (n = 70)\nAlirocumab (n = 561)\nPlacebo (n = 280)\n\n\n\nCalculated LDL-C, mg/dL\n\n Baseline, mean (SE)\n117.4 (1.6)\n119.1 (2.4)\n130.6 (1.5)\n128.7 (2.0)\n112.8 (3.6)\n119.8 (5.5)\n133.0 (2.0)\n132.5 (2.7)\n\n\n Calculated LDL-C at week 24, mean (SE)\n52.3 (1.5)\n116.8 (2.1)\n50.2 (1.1)\n124.4 (1.5)\n71.1 (3.5)\n122.5 (4.7)\n63.1 (1.6)\n136.4 (2.2)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 59.9 (1.2)\n− 1.4 (1.7)\n− 60.6 (0.9)\n1.5 (1.3)\n− 43.8 (2.5)a\n\n0.3 (3.4)\n− 49.7 (1.6)a\n\n5.1 (1.6)\n\n\n  Percentage difference vs placebo\n− 58.5 (2.1)\n− 62.1 (1.5)\n− 44.0 (4.1)\n− 54.8 (2.0)\n\n\n  Interaction p value\n0.1600\n0.0201\n\n\nPercentage of persons achieving LDL-C < 70 mg/dL at week 24\n77.7\n10.3\n76.8\n6.4\n68.3\n5.9\n65.8\n2.8\n\n\n Interaction p value\n0.0188\n0.2525\n\nOther lipids, mg/dL\n\n Apo B, baseline, mean (SE)\n101.7 (1.1)\n100.6 (1.7)\n104.2 (1.0)\n104.4 (1.3)\n99.5 (2.5)\n100.4 (3.4)\n107.6 (1.3)\n107.3 (1.6)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.6 (1.1)\n1.1 (1.6)\n− 53.5 (0.8)\n0.6 (1.2)\n− 34.4 (2.0)\n− 0.3 (2.6)\n− 41.6 (0.9)\n1.3 (1.2)\n\n\n  Percentage difference vs placebo\n− 50.7 (2.0)\n− 54.1 (1.4)\n− 34.0 (3.2)\n− 42.9 (1.5)\n\n\n  Interaction p value\n0.1608\n0.0121\n\n\n Lp(a), baseline, mean (SE)\n34.9 (1.8)\n34.9 (2.3)\n48.4 (1.6)\n46.1 (2.2)\n61.2 (6.3)\n54.7 (6.9)\n48.4 (2.2)\n47.5 (3.2)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 28.5 (1.2)\n− 2.0 (1.8)\n− 29.3 (0.9)\n− 5.1 (1.2)\n− 18.1 (2.4)\n− 7.6 (3.2)\n− 26.5 (1.1)\n− 7.7 (1.5)\n\n\n  Percentage difference vs placebo\n− 26.5 (2.1)\n− 24.2 (1.5)\n− 10.5 (4.0)\n− 18.8 (1.9)\n\n\n  Interaction p value\n0.3861\n0.0581\n\n\n Non-HDL-C, baseline, mean (SE)\n151.4 (1.8)\n151.3 (2.7)\n158.1 (1.6)\n157.5 (2.2)\n143.2 (3.8)\n149.5 (5.9)\n158.6 (2.2)\n156.9 (2.8)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n− 49.1 (1.1)\n− 0.3 (1.5)\n− 52.2 (0.8)\n0.8 (1.1)\n− 36.0 (2.3)\n2.6 (3.1)\n− 43.0 (1.1)\n5.2 (1.5)\n\n\n  Percentage difference vs placebo\n− 48.8 (1.8)\n− 53.0 (1.3)\n− 38.7 (3.7)\n− 48.2 (1.8)\n\n\n  Interaction p value\n0.0603\n0.0218\n\n\n TGs, baseline, mean (SE)\n172.1 (4.3)\n163.5 (4.9)\n137.8 (2.2)\n144.7 (3.3)\n155.5 (8.6)\n148.7 (8.0)\n129.0 (3.0)\n122.9 (3.6)\n\n\n  Percentage change from baseline to week 24, adjusted mean (SE)\n− 12.2 (1.4)\n6.3 (2.0)\n− 16.8 (1.0)\n− 0.6 (1.4)\n− 7.7 (2.7)\n2.4 (3.6)\n− 9.1 (1.2)\n1.2 (1.7)\n\n\n  Percentage difference vs placebo\n− 18.5 (2.4)\n− 16.2 (1.7)\n− 10.1 (4.3)\n\n− 10.3 (2.1)\n\n\n  Interaction p value\n0.4319\n0.9659\n\n\n HDL-C, baseline, mean (SE)\n48.3 (0.5)\n48.6 (0.7)\n50.7 (0.4)\n50.4 (0.5)\n44.5 (1.1)\n45.9 (1.4)\n51.9 (0.7)\n50.7 (0.9)\n\n\n  Percentage change from baseline to week 24, LS mean (SE)\n2.3 (0.6)\n− 1.0 (0.9)\n5.1 (0.5)\n− 0.1 (0.6)\n5.3 (1.4)\n− 2.4 (1.9)\n6.9 (0.7)\n− 0.7 (0.9)\n\n\n  Percentage difference vs placebo\n3.3 (1.1)\n\n5.1 (0.8)\n\n7.6 (2.3)\n7.5 (1.1)\n\n\n  Interaction p value\n0.1680\n0.9692\n\n\n\nOpen in a new tab\n\nApo apolipoprotein, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), LS least-squares, Q2W every 2 weeks, SE standard error, TG triglyceride\naAt week 12, 26.2% of subjects with DM and 36.4% of those without DM received dose increase of 75 mg Q2W to 150 mg Q2W\nFig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regardless of high-intensity statin status, the LDL-C percentage change from baseline to week 24 was similar in participants with and without DM (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C levels were maintained through 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The reductions up to 78 weeks for the ITT population are presented in Supplementary Fig. 2A.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subgroup analysis with and without high-intensity statin demonstrated similar LDL-C reductions at week 24, regardless of DM status (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "LDL-C reductions were maintained with alirocumab 75/150 mg Q2W until end of study treatment, regardless of DM status, in the on-treatment population (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similar LDL-C reductions were observed in the ITT population (Supplementary Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Reduced levels of other lipids were observed from week 4 and maintained for up to 78 weeks in individuals with and without DM in the on-treatment population (Fig. 2b–f).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The lipid levels for the ITT population were similar (Supplementary Fig. 2B–F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "No correlation was found between baseline HbA1c levels and LDL-C reductions in alirocumab-treated individuals with DM at week 24 (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]